Prothena (PRTA) announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint. Based on these results, the company will discontinue the development of birtamimab, including stopping the open label extension of the AFFIRM-AL clinical trial. In the Phase 3 AFFIRM-AL clinical trial, the primary endpoint of time to all-cause mortality was not met for patients treated with birtamimab. In addition, neither of the secondary endpoints were met: 6-minute walk test distance and Short Form-36 version 2 Physical Component Score. Birtamimab was generally safe and well-tolerated, consistent with its established safety profile. In June, the company expects to provide details of plans to reduce ongoing operating expenses. The results of the company’s review of its business options will be communicated as appropriate once the analysis and plans are finalized.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue